Edition:
United Kingdom

Allergan And Editas Medicine Announce To Jointly Develop Crispr Genome Editing Experimental Medicine Edit-101


Monday, 6 Aug 2018 

Aug 6 (Reuters) - Allergan plc ::ALLERGAN AND EDITAS MEDICINE ANNOUNCE EXERCISE OF OPTIONS TO JOINTLY DEVELOP CRISPR GENOME EDITING EXPERIMENTAL MEDICINE EDIT-101.EXERCISED OPTION TO DEVELOP & COMMERCIALIZE EDIT-101 GLOBALLY FOR TREATMENT OF LCA10.HAS PAID EDITAS MEDICINE A FEE OF $15 MILLION IN CONJUNCTION WITH EXERCISE OF ITS OPTION.ADDITIONALLY, EDITAS MEDICINE HAS EXERCISED ITS OPTION TO CO-DEVELOP, SHARE EQUALLY IN PROFITS AND LOSSES FROM EDIT-101 IN U.S..EDITAS MEDICINE ELIGIBLE TO RECEIVE ADDITIONAL $25 MILLION FROM ALLERGAN UPON ACCEPTANCE OF IND APPLICATION FOR EDIT-101 BY FDA.